DNA Ginkgo Bioworks Holdings, Inc. Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
18:25
Aug 19
rosannainvests Founder, CEO & Chief Investment Strategist, Hydra Wealth Advisors
Author acknowledges a biotech list with eye emojis but gives no explicit position or forward.
Author acknowledges a biotech list with eye emojis but gives no explicit position or forward call, so all tickers are indexed as watch.
DNA
LOW
14:33
Jun 04
Speaker notes price momentum in $DNA after previously cutting a long position.
Speaker notes price momentum in $DNA after previously cutting a long position; no current directional commitment.
DNA
LOW
14:17
Jun 03
Author exits DNA position for portfolio management reasons, not due to a change in thesis.
Author exits DNA position for portfolio management reasons, not due to a change in thesis, so no forward directional call is made.
DNA
20:25
Jun 02
temple_eight AI Photonics Trader
Speaker expresses favorable view on $DNA but considers it premature; no trade commitment.
DNA
LOW
19:57
Jun 02
The author warns that the digital biology narrative will cause many biotechs to rerate without.
The author warns that the digital biology narrative will cause many biotechs to rerate without fundamental support, advising caution on picking the right names rather than taking a directional position.
DNA
19:24
Jun 02
Buy DNA speculatively on the Microsoft partnership and OpenAI collaboration.
Buy DNA speculatively on the Microsoft partnership and OpenAI collaboration, betting AI-driven biotech theme gains momentum.
DNA 2ND
MED
12:01
Mar 24
Jason Kelly Co-host, The Deal Podcast Sequoia Capital
Ginkgo commercializes autonomous labs for AI science
Ginkgo has built and is commercializing the automated, AI-driven lab infrastructure for experimental science. Its Boston lab runs about 50 robots scaling toward 100, with in-house scientists dogfooding the system; it sells reconfigurable automation racks on a per-box service fee plus software subscription (97 sold to the Department of Energy for the Genesis mission); and it launched a cloud lab service with experiments as cheap as $39. The OpenAI collaboration showed a reasoning model with a robotic lab beating the state-of-the-art cell-free protein synthesis benchmark by 40% after six rounds of ~30,000 experiments by running 24/7 and sharing data across 100 parallel hypotheses, validating Ginkgo's bet that removing humans from the bench collapses discovery costs, lifts lab utilization from under 20% toward 70%, and captures a large new market.
DNA 1ST
HIGH
08:02
Mar 02
Noah Smith Economist; ex-columnist, Bloomberg Opinion Noahpinion
The article explicitly describes a collaboration between Google and Ginkgo Bioworks where GPT-5 connected to an autonomous lab reduced protein production cost by 40% and compressed 150 years of work i
The article explicitly describes a collaboration between Google and Ginkgo Bioworks where GPT-5 connected to an autonomous lab reduced protein production cost by 40% and compressed 150 years of work into weeks. This validates Ginkgo's platform-as-a-service model and signals growing commercial adoption of AI-driven synthetic biology. Risk: Partnership dependency on Google; Ginkgo's revenue still small and path to profitability uncertain.
DNA
20:34
Feb 09
Long $DNA — speaker explicitly states 'I've also begun a starter position in $DNA today' citing.
Long $DNA — speaker explicitly states 'I've also begun a starter position in $DNA today' citing Ginkgo Bioworks' Autonomous Laboratory + OpenAI GPT-5 milestone achieving 40% improvement over state-of-the-art benchmark.
DNA 1ST
HIGH
14:43
Aug 11
Absurd valuations point to total investor loss.
Author expects a total loss for investors due to absurd valuations since the company went public.
DNA
MED

About DNA Investor Commentary

Across the available history and selected sources, Buzzberg tracks DNA (Ginkgo Bioworks Holdings, Inc.) across 7 sources: 3 bullish vs 0 bearish calls from 7 authors. Historical directional balance: 30% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 10 total trade ideas tracked. Latest voices: rosannainvests, thematictrader, temple_eight.